Download PDF
Thromb Haemost 2008; 99(06): 1132-1134
DOI: 10.1160/TH07-12-0748
Letters to the Editor
Schattauer GmbH

Homocysteine levels in patients with deep vein thrombosis lacking thrombophilic defects

Amparo Vayá
1   Haemorheology and Thrombosis Unit, Department of Clinical Pathology, La Fe University Hospital Valencia, Spain
,
Inés Gómez
1   Haemorheology and Thrombosis Unit, Department of Clinical Pathology, La Fe University Hospital Valencia, Spain
,
Yolanda Mira
1   Haemorheology and Thrombosis Unit, Department of Clinical Pathology, La Fe University Hospital Valencia, Spain
,
Fernando Ferrando
1   Haemorheology and Thrombosis Unit, Department of Clinical Pathology, La Fe University Hospital Valencia, Spain
,
Dolores Corella
2   Genetic and Molecular Epidemiology Unit, School of Medicine, and CIBER Fisiopatología de la Obesidad y Nutrición CB06/03, University of Valencia, Spain
› Author Affiliations
Further Information

Publication History

Received 20 December 2007

Accepted after major revision 09 April 2008

Publication Date:
28 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Cattaneo M. Hyperhomocysteinemia and venous thromboembolism. Semin Thromb Hemost 2006; 32: 716-723.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Gatt A, Makris M. Hyperhomocysteinemia and venous thrombosis. Semin Hematol 2007; 44: 70-76.
    CrossrefPubMedGoogle Scholar
  • 3 den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a metaanalysis of published epidemiological studies. J Thromb Haemost 2005; 3: 292-299.
    CrossrefPubMedGoogle Scholar
  • 4 Frederiksen J, Juul K, Grande P. et al. Methylenetetrahydrofolate reductase polymorphism (C677T), hyperhomocysteinemia, and risk of ischemic cardiovascular disease and venous thromboembolism: prospective and casecontrol studies from the Copenhagen City Heart Study. Blood 2004; 104: 3046-3051.
    CrossrefPubMedGoogle Scholar
  • 5 Marcucci R, Gori AM, Abbate R. Hyperhomocysteinemia: cause or effect of disease?. Blood 2005; 105: 3382-3383.
    PubMedGoogle Scholar
  • 6 Schneede J, Refsum H, Ueland PM. Biological and environmental determinants of plasma homocysteine. Semin Thromb Hemost 2000; 26: 263-279.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Brattström L, Tengborn L, Lagerstedt C. et al. Plasma homocysteine in venous thromboembolism. Haemostasis 1991; 21: 51-57.
    PubMedGoogle Scholar
  • 8 Den Heijer M, Blom HJ, Gerrits WBJ. et al. Is hyperhomocysteinemia a risk factor for recurrent venous thrombosis?. Lancet 1995; 345: 882-885.
    CrossrefPubMedGoogle Scholar
  • 9 Ridker PM, Hennekens CH, Selhub J. et al. Interrelation of hyperhomocysteinemia, factor V Leiden and risk of future venous thromboembolism. Circulation 1997; 95: 1777-1782.
    CrossrefPubMedGoogle Scholar
  • 10 den Heijer M, Koster T, Blom HJ. et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334: 759-762.
    CrossrefPubMedGoogle Scholar
  • 11 Lijfering WM, Coppens M, van de Poel MHW. et al. The risk of venous and arterial thrombosis in hyperhomocysteinaemia is low and mainly depends on concomitant thrombophilic defects. Thromb Haemost 2007; 98: 457-463.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Martínez-Frias ML, Bermejo E, Rodríguez-Pinilla E. et al. Frequency of the mutation 677C-T of methylenetetrahydrofolate reductase gene on a sample of 652 Spanish liveborn infants. Med Clin (Barc) 2004; 122: 361-364.
    CrossrefPubMedGoogle Scholar
  • 13 Corella D, Cortina P, Guillen M. et al. Dietary habits and geographical variation in stomach cancer mortality in Spain. Eur J Cancer Prev 1996; 5: 249-257.
    CrossrefPubMedGoogle Scholar
  • 14 Vargas M, Soto I, Pinto CR. et al. Mild hyperhomocysteinemia and MTHFR C677-T do not increase the risk for venous thrombosis in a Spanish population. Blood Coagul Fibrin 1998; 9: 555-556.
    CrossrefPubMedGoogle Scholar
  • 15 González Y, Souto JC, Mateo J. et al. Moderate hyperhomocysteinemia is a highly prevalent defect in Spanish patients with venous thromboembolic disease. Haematologica 1998; 83: 1126-1127.
    PubMedGoogle Scholar
  • 16 Dudman NP. An alternative view of homocysteine. Lancet 1999; 354: 2072-2074.
    CrossrefPubMedGoogle Scholar
  • 17 Ricart JM, Vayá A, Todolí J. et al. Thrombophilic risk factors and homocysteine levels in Behçet’s disease in eastern Spain and their association with thrombotic events. Thromb Haemost 2006; 95: 618-624.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Keijzer MB, den Heijer M, Blom HJ. et al. Interaction between hyperhomocysteinemia, mutated methylenetetrahydrofolatereductase (MTHFR) and inherited thrombophilic factors in recurrent venous thrombosis. Thromb Haemost 2002; 88: 723-728.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Hankey GJ, Elkelboom JW. Homocysteine and vascular disease. Lancet 1999; 354: 407-413.
    CrossrefPubMedGoogle Scholar
  • 20 Ray J, Gmm Kearon C, Yi Q, Sheridan P. et al. Heart Outcomes Prevention Evaluation 2 (HOPE-2) Investigators. Homocysteine-lowering therapy and risk for venous thromboembolism: a randomised trial. Ann Intern Med 2007; 146: 761-767.
    CrossrefPubMedGoogle Scholar
  • 21 den Heijer M, Willems HP, Blom HJ. et al. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trial. Blood 2007; 109: 139-144.
    CrossrefPubMedGoogle Scholar